DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde


Moebus V, Jackisch C, Lueck HJ. et al.
Ten-year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with ≥ 4 positive lymph nodes. SABCS 2012; Abstr. S3-04.

Download Bibliographical Data

Search in: